NCT06224257
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
StatusCompleted
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 23 words
- Trial completed
- Site details revised at 3 of 3 sites
- Minor Primary completion date: Jun 30, 2025 to Oct 31, 2025
- Study completion date: Oct 31, 2025 to Jan 31, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of patients with hematologic remission
Timeframe: 8-12 weeks
Secondary (1)
Incidence of the adverse event
Arms and interventions
LinperlisibExperimental
Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred.
Drugs: Linperlisib
Sites
3 sites in 1 country